Insider trade

Officer sold ~$951K of EW shares in the open market

Traded Dec 10, 2025 · Filed Dec 10, 2025

~$951K
Reported value · 11K sh @ $83.8255: 50K
Holds after · shares reported: +1.5%
stock since the trade · S&P 500 +11.1%, $83.92 → $85.19 on Oct 1

Why it stands out

Edwards Lifesciences's CVP,Strategy/Corp Development sold $951K of Edwards Lifesciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 10, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 10, 2025

Officer$500K–$1MPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$950,581

Shares × reported transaction price

Timing vs results

41 days after results of Oct 30, 2025, 62 days before results of Feb 10, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $83.92 on Dec 10, 2025, within 4% of its 52-week high, after a 2% rise over the previous 30 trading days

52-week range $67.07 (Apr 8, 2025) to $86.82 (Nov 25, 2025), 85% of the way up, from 250 adjusted closes. 30 trading days earlier: $82.19 on Oct 28, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.

Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved SAPIEN M3 Transcatheter Mitral Valve Replacement System on Dec 22, 2025, 12 days after this trade.

Premarket approval (PMA): Prosthesis, mitral valve, percutaneously delivered. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.7%	-1.8%	+2.5%
30 days	-1.5%	+0.9%	-2.3%
90 days	+1.0%	-1.9%	+2.9%
180 days	+3.9%	+7.0%	-3.0%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-25-009841
Filed / recorded: Dec 10, 2025, 11:58 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Edwards Lifesciences Corp
Issuer CIK: 1099800
Ticker: EW
Reporting person: Donald E Jr Bobo
Relationship: Officer
Officer title: CVP,Strategy/Corp Development
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Dec 10, 2025
Transaction code: S
Shares / units: 11,340
Price per share: $83.8255
Acquired / disposed: Disposed (D)
Shares owned after: 50,356.3707
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
This transaction was executed in multiple trades at prices ranging from $83.465 to $84.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.